Loading...
Infliximab is superior to placebo for induction of remission in active Crohn's disease and for closure of fistulae, but relapse is common after discontinuation. In the largest randomized, controlled trial of patients with Crohn's disease to date, researchers evaluated maintenance therapy with infliximab: 573 patients with Crohn's disease activity indexes (CDAIs) ≥220 received single initial infusions of infliximab (5 mg/kg). At week 2, 58% of patients had responded; these patients were then randomized to receive repeat infusions of 1 of the following maintenance regimens at weeks 2 and 6, and then every 8 weeks until week 46: Placebo (group 1), infliximab (5 mg/kg; group 2), or infliximab (5 mg/kg) at weeks 2 and 6 followed by 10 mg/kg ever…